Lisa Cook sues Trump over firing attempt, emergency hearing set
CAMBRIDGE, Mass. – Beam Therapeutics Inc. (NASDAQ:BEAM), a $1.59 billion market cap biotechnology company whose shares are currently trading at $16.32, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BEAM-302, its investigational treatment for alpha-1 antitrypsin deficiency (AATD), the company announced today. AATD is a rare inherited disorder that can lead to severe lung and liver disease, and there is a significant need for effective therapies. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value calculation.
The FDA grants orphan drug status to encourage the development of treatments for rare diseases affecting fewer than 200,000 people in the U.S. This designation provides Beam Therapeutics with incentives such as tax credits, fee waivers, and the potential for seven years of market exclusivity upon approval. Analysts maintain a bullish stance on BEAM, with price targets ranging from $20 to $80 per share, suggesting significant upside potential. For detailed analysis and more insights, check out the comprehensive research report available on InvestingPro.
BEAM-302 is a liver-targeting lipid-nanoparticle formulation designed to correct the disease-causing mutation in AATD patients. The treatment has shown promise in initial safety and efficacy data from an ongoing Phase 1/2 trial. In March, Beam reported that the drug was well tolerated and led to dose-dependent correction of the mutation and increased protein levels in patients.
The company has begun dosing in the fourth cohort of the study and plans to present updated data later in the year. Part B of the trial, which will include patients with mild to moderate liver disease, is expected to commence in the second half of 2025.
Previously, BEAM-302 received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and clearance for a U.S. investigational new drug application in March 2025. Despite the stock’s YTD decline of about 32%, the company maintains a strong financial position with a healthy current ratio of 8.81. InvestingPro rates Beam’s overall financial health as FAIR, based on comprehensive analysis of multiple financial metrics and growth indicators.
Beam Therapeutics specializes in precision genetic medicines through base editing, a technology that enables precise, predictable, and efficient single base changes in DNA. The company’s focus is on providing life-long cures to patients with serious diseases using its suite of gene editing technologies.
The orphan drug designation for BEAM-302 highlights the FDA’s recognition of the need for new treatments for AATD and the potential for this therapy to address the root cause of the illness. Beam Therapeutics remains committed to the advancement of BEAM-302 with the goal of delivering a one-time, potentially curative treatment. This news is based on a press release statement from Beam Therapeutics.
In other recent news, Beam Therapeutics Inc. has made significant strides with its gene-editing treatment, BEAM-302, which targets alpha-1 antitrypsin deficiency (AATD). The company announced that BEAM-302 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA), following earlier FDA approval for its investigational new drug application. This designation could facilitate faster development and review processes for the therapy. Additionally, Beam Therapeutics presented promising data from its Phase 1/2 trial at a global research conference, showing substantial correction of the PiZ mutation in AATD patients. Both H.C. Wainwright and BofA Securities have expressed optimism, with H.C. Wainwright maintaining a Buy rating and an $80 price target, while BofA upgraded the stock to Buy with a $42 target, citing reduced risks and appealing valuation. Furthermore, Bernstein has maintained its Outperform rating with a $37 target, highlighting anticipated positive data developments in the coming year. Beam Therapeutics continues to focus on advancing its pipeline, which includes treatments for other genetic disorders, positioning it as a leader in precision genetic medicines.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.